Financials data is unavailable for this security.
View more
Year on year Viridian Therapeutics Inc 's revenues fell -82.28% from 1.77m to 314.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 129.87m to a larger loss of 237.73m.
| Gross margin | -- |
|---|---|
| Net profit margin | -85,127.15% |
| Operating margin | -93,722.52% |
| Return on assets | -46.71% |
|---|---|
| Return on equity | -77.05% |
| Return on investment | -49.63% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Viridian Therapeutics Inc fell by 52.75m. Cash Flow from Financing totalled 225.67m or 71,869.43% of revenues. In addition the company used 184.17m for operations while cash used for investing totalled 94.25m.
| Cash flow per share | -4.25 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.94 |
|---|---|
| Tangible book value per share | 8.94 |
More ▼
Balance sheet in USDView more
| Current ratio | 18.55 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.029 |
|---|---|
| Total debt/total capital | 0.0282 |
More ▼
